Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

D-915

Supelco

Desalkylflurazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H10ClFN2O
CAS Number:
2886-65-9
Molecular Weight:
288.70
EC Number:
200-659-6
MDL number:
MFCD00083443
UNSPSC Code:
41116107
NACRES:
NA.24
Pricing and availability is not currently available. Contact Technical Service

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23

InChI

1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

InChI key

UVCOILFBWYKHHB-UHFFFAOYSA-N

Related Categories

General description

Desalkylflurazepam, also known as N-desalkyl-2-oxoquazepam, is a long-acting metabolite of the benzodiazepine drug flurazepam. Flurazepam is sold unde the trade names Dalmane and Dalmadorm for the treatment of mild to moderate insomnia. This Certified Spiking Solution® is suited for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis or urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

D-924

Desalkylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-003

Flurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-901

2-Hydroxyethylflurazepam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-902

2-Hydroxyethylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-919

2-Hydroxyethylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-923

2-Hydroxyethylflurazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kimiyasu Kato et al.
Therapeutic drug monitoring, 25(4), 473-477 (2003-07-29)
The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug were studied. Ten healthy male volunteers received itraconazole 100
I Conti et al.
European journal of drug metabolism and pharmacokinetics, 16(1), 53-58 (1991-01-01)
The influence of propranolol on the disposition of flutoprazepam, a benzodiazepine derivative extensively biotransformed by hepatic microsomal oxidation, was evaluated in the rat. Propranolol was infused subcutaneously with osmotic minipumps (5 mg/day) to obtain steady-state concentrations of about 200 ng/ml.
H Morishita et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 86(1), 71-85 (1985-07-01)
Pharmacodynamic effects of ethyl 7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1H-1,4- benzodiazepine-3-carboxylate (CM6912), a new benzodiazepine derivative, and its main metabolites (CM6913 = M1, CM7116 = M2) on the peripheral systems were investigated in several species of animals. In pentobarbital-anesthetized rabbits, CM6912 and M2 (1 or
[Pharmacokinetics of the two major metabolites of ethyl loflazepate (CM6912) in dogs and humans. Simulation by a digital computer].
M Ito et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 106(8), 703-708 (1986-08-01)
J M Hilbert et al.
Journal of clinical pharmacology, 24(10), 457-462 (1984-10-01)
Previous metabolic studies have established that two major metabolites, 2-oxoquazepam and N-desalkyl-2-oxoquazepam, are present in plasma after dosing with quazepam, a new benzodiazepine hypnotic. The excretion of quazepam, 2-oxoquazepam, and N-desalkyl-2-oxoquazepam into human breast milk was studied in four lactating
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service